Insiders · PCVX

Michael E. Kamarck

Director at Vaxcyte, Inc. (PCVX) since October 2021

Michael E. Kamarck has filed 8 insider reports with the SEC since October 2021, as director at Vaxcyte, Inc. (PCVX), director at Passage BIO, Inc. (PASG) and director at Trillium Therapeutics Inc. (TRIL). The latest filing, on June 15, 2023, reports grant or award at Vaxcyte, Inc. (PCVX).

Filings
8
Companies
3
Bought on market
None
Sold on market
None

Companies where Michael E. Kamarck is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Vaxcyte, Inc. logo
PCVX
Vaxcyte, Inc.
Directorsince October 20215,625$55.39Jun 15, 2023
Passage BIO, Inc. logo
PASG
Passage BIO, Inc.
Directorsince July 2022$3.92May 26, 2023
Trillium Therapeutics Inc. logo
TRIL
Trillium Therapeutics Inc.
Director$20.4795Nov 19, 2021

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Michael E. Kamarck with

Other insiders at the same companies

Questions about Michael E. Kamarck

What is Michael E. Kamarck's role at Vaxcyte, Inc.?
Michael E. Kamarck reports to the SEC as director at Vaxcyte, Inc. (PCVX), according to the latest filing on June 15, 2023. Michael E. Kamarck has also filed as director at Passage BIO, Inc. (PASG) and director at Trillium Therapeutics Inc. (TRIL).
How many shares does Michael E. Kamarck own?
After the latest filing that states it, Michael E. Kamarck directly owned 5,625 shares of Vaxcyte, Inc. (PCVX). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Michael E. Kamarck bought or sold stock recently?
No open-market purchases or sales by Michael E. Kamarck are on file. The filings report grant or award and sale back to the company.
How do I get alerts when Michael E. Kamarck files?
Follow Michael E. Kamarck on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Michael E. Kamarck (SEC CIK 0001450730). Totals count each trade once, skipping amendments whose original is on file, from Oct 29, 2021 on. View on SEC EDGAR · Get this as JSON